

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

18-401 / S-014

APPROVAL LETTER



NDA 18-401/S-014

Reckitt Benckiser Pharmaceuticals, Inc.
1909 Huguenot Road
Richmond, VA 23235

Attention: Alan Young
Director, Regulatory Affairs

Dear Mr. Young:

Please refer to your supplemental new drug application dated January 17, 2001, received January 19, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Buprenex (buprenorphine hydrochloride) Injectable.

We acknowledge receipt of your submission dated November 16, 2001, received November 26, 2001.

This supplemental new drug application provides for revisions to the "**Drug Interactions**" and the "**Carcinogenesis, Mutagenesis and Impairment of Fertility**" subsections of the **PRECAUTIONS** section. The cartons and containers were updated to reflect the new company name.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted November 19, 2001, immediate container and carton labels submitted November 19, 2001).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 18-401/S-014." Approval of this submission by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Sara Shepherd, Project Manager, at (301) 827-7430.

Sincerely,

{See appended electronic signature page}

Cynthia McCormick, M.D.
Director
Division of Anesthetic, Critical Care,
and Addiction Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Cynthia McCormick
2/11/02 05:33:22 PM